ABCL-1001: Cellular Kinetics, Efficacy, and Safety of Zamtocabtagene Autoleucel, a Tandem CD20/CD19-Directed CAR T-Cell Therapy, vs R-GemOx in Patients With Relapsed/Refractory LBCL (DALY 2-EU Study)
作者
Nirav Niranjan Shah,Peter Borchmann,Gloria Iacoboni,Tom van Meerten,Pierre Bories,Peter Dreger,László Gopcsa,Pim G. N. J. Mutsaers,Matthias Edinger,Lajos Gergely,Bastian von Tresckow,Peter Neumeister,Normann Steiner,Ulrich Jaeger,Ana Triguero Moreno,Laimonas Griškevičius,François Lemonnier,Jaap A. van Doesum,Rimas Orentas,Birte Friedrichs